| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/18/2009 | CA2733797A1 Methods for inhibition of scarring |
| 06/18/2009 | CA2733794A1 Methods for the inhibition of scarring |
| 06/18/2009 | CA2709153A1 Impaired wound healing compositions and treatments |
| 06/18/2009 | CA2709151A1 Impaired wound healing compositions and treatments |
| 06/18/2009 | CA2709027A1 Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) |
| 06/18/2009 | CA2709007A1 Methods for inhibiting scarring |
| 06/18/2009 | CA2708613A1 Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith |
| 06/18/2009 | CA2708343A1 Method for increasing immunoreactivity |
| 06/18/2009 | CA2708229A1 Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor |
| 06/18/2009 | CA2708134A1 Cyclic protein free from cysteines |
| 06/18/2009 | CA2707850A1 Reverse protein |
| 06/18/2009 | CA2707733A1 Advantageous salts of mu-opiate receptor peptides |
| 06/18/2009 | CA2707132A1 Insulinotropic peptide synthesis using solid and solution phase combination techniques |
| 06/17/2009 | EP2071338A2 Human diabetes-mediating proteins |
| 06/17/2009 | EP2071036A2 Methods for identifying RNA-binding compounds |
| 06/17/2009 | EP2071030A2 Oligoribonucleotide or peptide nucleic acid which inhibits action of hepatitis C virus |
| 06/17/2009 | EP2071028A2 HLA-DR-binding antigen peptide derived from WT1 |
| 06/17/2009 | EP2070949A2 Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 06/17/2009 | EP2070946A2 Invention affecting GLP-1 and Exendin |
| 06/17/2009 | EP2070944A1 Specific binding agents of human angiopoietin-2 |
| 06/17/2009 | EP2070939A1 Modulators of pharmacological agents |
| 06/17/2009 | EP2070550A1 Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases |
| 06/17/2009 | EP2070549A1 Therapeutic agent for acceleration of spinal nerve repair comprising desacyl ghrelin or derivative thereof as active ingredient |
| 06/17/2009 | EP2070547A1 Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor |
| 06/17/2009 | EP2070546A1 Preventives/remedies for cancer |
| 06/17/2009 | EP2069490A2 Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them |
| 06/17/2009 | EP2069486A2 Phytases with improved thermal stability |
| 06/17/2009 | EP2069399A2 Interferons of rhesus and cynomolgus origin and uses thereof |
| 06/17/2009 | EP2069392A2 Tnf superfamily fusion proteins |
| 06/17/2009 | EP2069388A2 Peptides derived from the c2 domain of epsilon pkc, and use thereof |
| 06/17/2009 | EP2069377A2 Methods and compositions for the treatment of skin diseases and disorders |
| 06/17/2009 | EP2068949A1 Antimicrobial and immunostimulatory system comprising an oxidoreductase enzyme |
| 06/17/2009 | EP2068937A2 Polymer-stabilized liposomal compositions and methods of use |
| 06/17/2009 | EP2068911A2 Methods for treating cancer |
| 06/17/2009 | EP2068910A2 Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition |
| 06/17/2009 | EP2068909A2 Modified fgf-21 polypeptides and their uses |
| 06/17/2009 | EP2068908A1 A milk protein composition and use thereof |
| 06/17/2009 | EP2068907A2 Glycerol linked pegylated sugars and glycopeptides |
| 06/17/2009 | EP2068906A1 Antiviral agent against animal viruses |
| 06/17/2009 | EP2068905A2 Albumin fusion proteins |
| 06/17/2009 | EP2068889A1 Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
| 06/17/2009 | EP2068887A2 Sp35 antibodies and uses thereof |
| 06/17/2009 | EP2068877A2 Compounds and methods of modulating angiogenesis |
| 06/17/2009 | EP2068874A1 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
| 06/17/2009 | EP2068830A2 Modified two-component gelation systems for the treatment of post-myocardial infarction |
| 06/17/2009 | EP2068629A2 Compositions and methods for treating cancer |
| 06/17/2009 | EP2068622A2 Method and mixture for in-vivo photochemical cross-linking of collagen |
| 06/17/2009 | EP1896386A4 Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria |
| 06/17/2009 | EP1855711B1 USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS |
| 06/17/2009 | EP1791423A4 Compositions and methods for the management of hyperproliferative dermatological conditions |
| 06/17/2009 | EP1740154B1 Insulin compositions with improved absorption |
| 06/17/2009 | EP1655036A4 Method for treating oncological diseases |
| 06/17/2009 | EP1649862A4 Agent for preventing and curing pathological states associated with endorphin deficiency in organism |
| 06/17/2009 | EP1648933B1 Long lasting insulin derivatives and methods thereof |
| 06/17/2009 | EP1575656B1 Insulin delivery system with sensor |
| 06/17/2009 | EP1465652A4 Povidone-containing carriers for polypeptide growth factors |
| 06/17/2009 | EP1390408A4 A molecular marker |
| 06/17/2009 | EP1177304B1 Modified factor viia polypeptides |
| 06/17/2009 | EP1147205B1 High efficiency mammalian gene expression vectors that contain exogenous promoter and entire 5' untranslated region in the upstream from start codon for inherent gene as transcription regulatory site |
| 06/17/2009 | EP1140131B1 Peptides and peptide analogues designed from hfe protein and their uses in the treatment of iron overload diseases |
| 06/17/2009 | EP1015496B1 Divalent anti-t cells immunotoxins and use thereof |
| 06/17/2009 | CN101460191A Stable formulation comprising moisture sensitive drugs and manufacturing procedure thereof |
| 06/17/2009 | CN101460190A High frequency application of neurotoxic component of botulinum toxin |
| 06/17/2009 | CN101460189A Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units |
| 06/17/2009 | CN101460188A Treatment of ischemic disease using erythropoietin |
| 06/17/2009 | CN101460187A Antisecretory protein for use in the treatment of compartment syndrome |
| 06/17/2009 | CN101455837A Collagen protein micro-pill and preparation method thereof |
| 06/17/2009 | CN101455836A Intraocular injection for treating infectious endophthalmitis |
| 06/17/2009 | CN101455835A Protein polypeptide composite nutrient-fluid microspheres capable of relieving or neutralizing the effect of alcohol and preparation method thereof |
| 06/17/2009 | CN100501400C Methods of protecting against radiation damage using alpha thymosin |
| 06/17/2009 | CN100500853C Fusion protein for secretion of protein of interest in supernatant of bacterial culture |
| 06/17/2009 | CN100500849C Expressing Ompk antigen of outer-membrane protein of Vibrio Harveyi and application as constituent of bacteria |
| 06/17/2009 | CN100500846C Human cytokine as ligand of zalpha receptor and use thereof |
| 06/17/2009 | CN100500692C Novel LHRH antagonists, preparation method and pharmaceutical use thereof |
| 06/17/2009 | CN100500658C Pharmaceutical composition of male sexual dysfunction |
| 06/17/2009 | CN100500654C Tetrahydrocarbazol derivatives as ligands for g-protein-coupled receptors (gpcr) |
| 06/17/2009 | CN100500211C Methods of therapy with thrombin derived peptides |
| 06/17/2009 | CN100500210C Use of il-18 inhibitors in hypersensitivity disorders |
| 06/17/2009 | CN100500209C CLK-peptide and SLK-peptide |
| 06/17/2009 | CN100500113C Stainless steel cardiovascular bracket with pharmaceutical coating on surface and preparation method thereof |
| 06/16/2009 | US7547773 Binding site amino acid sequences for use as targeting agents in immunotherapeutics; antitumor agents; which conforms to human leukocyte antigen (HLA) motifs; immunogens; cytotoxic T lymphocytes; comprises proteases; prostate cancer |
| 06/16/2009 | US7547766 Anti-tango294 antibodies and uses thereof |
| 06/16/2009 | US7547765 For modifying polypeptides; shikimic acid, quinic acid, or carbohydrate derivatives of polyalkylene glycols; improves bioavailability of modified peptides such as enzyme, a cytokine or a hormone e.g. interferon beta or granulocyte colony stimulating factor; biodrugs |
| 06/16/2009 | US7547763 Sequences of an Ih ion channel and use thereof |
| 06/16/2009 | US7547762 T24 antigen for immunodiagnosis of Taenia solium cysticercosis |
| 06/16/2009 | US7547761 For isolating low molecular weight peptides from animal tissue; prevention of initial dissolution of higher molecular weight fraction proteins by in situ denaturation within the tissue, by an organic solvent (preferably ethanol), prior to aqueous extraction |
| 06/16/2009 | US7547760 Using the anti-SHP2 peptides and SEBA compounds (4-(2-sulfaminoethyl)benzoic acid) reverses cell transformation and induces remission of preformed tumors in vivo demonstrating a possible treatment for cancer; phosphotyrosyl phosphatase |
| 06/16/2009 | US7547726 AI-2 compounds and analogs based on Salmonella typhimurium LsrB structure |
| 06/16/2009 | US7547678 Using expression vector comprising UDP-glucuronosyltransferase (UGTIAI) as gene transfer tool in treatment of hyperbilirubinemia |
| 06/16/2009 | US7547677 Peptide or fusion protein containing peptide binds to gut of sap-sucking insects, e.g., aphids; when bound, peptide inhibits binding of targeted virus to insect gut; when peptide is expressed in fluids of transgenic plants, is taken up by insect with sap, binds to gut receptors, inhibits transmission |
| 06/16/2009 | US7547676 Antagonist peptides to the C5A chemotactic function of vitamin D binding protein |
| 06/16/2009 | US7547675 Chemically modified polypeptides |
| 06/16/2009 | US7547674 By stimulating resident somatic stem cells; administering cytokines; kits |
| 06/16/2009 | US7547673 Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production |
| 06/16/2009 | US7547662 Target recognizing binding agents |
| 06/16/2009 | US7547521 Heteromultimeric ion channel receptor and uses thereof |
| 06/16/2009 | US7547517 complexes, expression vectors and host cells transformed or transfected with nucleic acid molecules encoding MAGE-C2; for provoking a cytolytic T cell response; for determining if a cell presents a Human Leukocyte Antigen(HLA) molecule on its surface; diagnostic and therapeutic assays; tumor monitoring |
| 06/16/2009 | US7547506 Using 6-carboxyfluorescein labeled mycobacterial amino acid sequences to detect infection; veterinary medicine |
| 06/16/2009 | US7547446 crosslinking gelatin with glutaraldehyde crosslinker in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran; useful for providing hemostasis at surgical bleeding sites and traumatic bleeding site |
| 06/16/2009 | US7547441 PAI-2 conjugates for the treatment and imaging of cancer |